Author

M. Feracci

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 3 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:structural biology· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

B. Canard· 3 shared F. Ferron· 3 shared A. Moussa· 2 shared E. Decroly· 2 shared J.-P. Sommadossi· 2 shared K. ALVAREZ· 2 shared S. Good· 2 shared A. Chazot· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

B. Canard

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

The activation chain of the broad-spectrum antiviral bemnifosbuvir at atomic resolution

A. Chazot, C. Zimberger, M. Feracci, A. Moussa, S. Good, J.-P. Sommadossi, K. ALVAREZ, F. Ferron, B. Canard

This paper reveals the activation pathway of bemnifosbuvir to its active form AT-9010, showing the required enzymes and structural insights into the process.

bioRxiv · Feb 16, 2024 · PreprintBiochemistry

A high-throughput fluorescence polarization assay to discover inhibitors of arenavirus and coronavirus exoribonucleases

S. G. Hernandez Tapia, M. Feracci, C. T. De Jesus, P. El-Kazzi, R. Kaci, L. Garlatti, E. Decroly, B. Canard, F. Ferron, K. Alvarez

This paper develops a high-throughput fluorescence polarization assay to screen inhibitors of exoribonucleases from arenaviruses and coronaviruses and validates it with a small compound library.

bioRxiv · Apr 2, 2021 · PreprintBiochemistry

Protein-primed RNA synthesis in SARS-CoVs and structural basis for inhibition by AT-527

A. Shannon, V. Fattorini, B. Sama, B. Selisko, M. Feracci, C. Falcou, P. Gauffre, P. El Kazzi, E. Decroly, N. Rabah, K. Toulon, C. Eydoux, J.-C. Guillemot, M. Noel, F. Debart, , B. Canard

This paper identifies a protein-priming mechanism for SARS-CoV RNA synthesis and shows that AT-527 inhibits this process by targeting both NiRAN and RdRp domains.

bioRxiv · Mar 23, 2021Biochemistry

In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor

J. Ariey-Bonnet, K. Carrasco, M. Le Grand, L. Hoffer, S. Betzi, M. Feracci, P. Tsvetkov, F. Devred, Y. Collette, X. Morelli, P. Ballester, E. Pasquier

This paper identifies mebendazole as a potent MAPK14 inhibitor through in silico target prediction and experimental validation, revealing its potential for repurposing in brain tumor treatment.

bioRxiv · May 18, 2020Pharmacology & Toxicology